A study on anti-tumor immunity induced by gene-modified melanoma B16 cells

Oncology Reports

Volumn 19, Issue 6, 2008, Pages 1589-1595

  Fang, Lijuan ^a   Wang, Kemin ^a   Liu, Xia ^a,b   Zhang, Leilei ^a,b   Zhang, Xingqian ^a   Qian, Li ^a   Lu, Jian ^a   Qian, Guangxiang ^a   Ge, Shengfang ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

CD80; Epitope fusion gene; Immunogene therapy; Interleukin 21; Melanoma

Indexed keywords

B7 ANTIGEN; CANCER VACCINE; INTERLEUKIN 21; BETA 2 MICROGLOBULIN; HYBRID PROTEIN; INTERLEUKIN DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CARCINOGENICITY; CELL GROWTH; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA MODIFICATION; DRUG SYNTHESIS; EXPRESSION VECTOR; FEMALE; FUSION GENE; MELANOMA; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY; ANIMAL; C57BL MOUSE; CD8+ T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL MELANOMA; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; METABOLISM; SURVIVAL RATE; VACCINATION;

ANIMALS; ANTIGENS, CD80; BETA 2-MICROGLOBULIN; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNITY, CELLULAR; INTERLEUKINS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; RECOMBINANT FUSION PROTEINS; SURVIVAL RATE; TRANSFECTION; VACCINATION;

EID: 48849099802     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Chan L, Hardwick NR, Guinn B-a, et al: An immune edited tumour versus a tumour edited immune system: prospects for immune therapy of acute myeloid leukaemia. Cancer Immunol Immunother 55: 1017-1024, 2006.
2. Kozlowski S, Takeshita T, Boehncke WH, et al: Excess beta 2 microglobulin promoting functional peptide association with purified soluble class I MHC molecules. Nature 349: 74-77, 1991.
3. Vitiello A, Potter TA and Sherman LA: The role of beta 2-microglobulin in peptide binding by class I molecules. Science 250: 1423-1426, 1990.
4. Qian L and Qian GX: In vivo CTL immunity can be elicited by OVA-linker-beta2m fusion protein. Sheng wu hua xue yu sheng wu wu li xue bao Acta biochimica et biophysica Sinica 34: 547-552, 2002.
5. Uger RA and Barber BH: Creating CTL targets with epitope-linked beta 2-microglobulin constructs. J Immunol 160: 1598-1605, 1998.
6. Schwartz RH: T cell anergy. Annu Rev Immunol 21: 305-334, 2003.
7. Carreno BM, Carter LL and Collins M: Therapeutic opportunities in the B7/ CD28 family of ligands and receptors. Curr Opin Pharmacol 5: 424-430, 2005.
8. Liu X, Zhang LL, Zhang XQ, et al: The effect of co-expression costimulatory molecule CD80 on uptake of antigen peptide-MHC class I-GFP complex by specific T cells. Int J Oncol 30: 1389-1396, 2007.
9. Parrish-Novak J, Dillon SR, Nelson A, et al: Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408: 57-63, 2000.
10. Kasaian MT, Whitters MJ, Carter LL, et al: IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 16: 559-569, 2002.
11. + T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL- 15, and IL-21. J Immunol 173: 900-909, 2004.
12. Engelhard VH: Structure of peptides associated with class I and class II MHC molecules. Annu Rev Immunol 12: 181-207, 1994.
13. Lurquin C, Van Pel A, Mariame B, et al: Structure of the gene of tumor transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells. Cell 58: 293-303, 1989.
14. Baskar S, Clements VK, Glimcher LH, Nabavi N and Ostrand-Rosenberg S: Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules. J Immunol 156: 3821-3827, 1996.
15. van Seventer GA, Newman W, Shimizu Y, et al: Analysis of T cell stimulation by superantigen plus major histocompatibility complex class II molecules or by CD3 monoclonal antibody: costimulation by purified adhesion ligands VCAM-1, ICAM-1, but not ELAM-1. J Exp Med 174: 901-913, 1991.
16. Rock KL, Fleischacker C and Gamble S: Peptide-priming of cytolytic T cell immunity in vivo using beta 2-microglobulin as an adjuvant. J Immunol 150: 1244-1252, 1993.
17. Ochsenbein AF, Sierro S, Odermatt B, et al: Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411: 1058-1064, 2001.
18. Zippelius A, Batard P, Rubio-Godoy V, et al: Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res 64: 2865-2873, 2004.
19. Langowski JL, Zhang X, Wu L, et al: IL-23 promotes tumour incidence and growth. Nature 442: 461-465, 2006.
20. Coutelier JP, Van Broeck J and Wolf SF: Interleukin-12 gene expression after viral infection in the mouse. J Virol 69: 1955-1958, 1995.
21. Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellstrom I and Hellstrom. KE: Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 179: 523-532, 1994.
22. + T lymphocytes. Cytokines Mol Ther 1: 211-221, 1995.
23. Chen L, Linsley PS and Hellstrom KE: Costimulation of T cells for tumor immunity. Immunol Today 14: 483-486, 1993.
24. Cavallo F, Martin-Fontecha A, Bellone M, et al: Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. Eur J Immunol 25: 1154-1162, 1995.
25. Liu Y, Wang H, Zhao J, Ma J, et al: Enhancement of immunogenicity of tumor cells by cotransfection with genes encoding antisense insulin-like growth factor-1 and B7.1 molecules. Cancer Gene Ther 7: 456-465, 2000.
26. Guo YJ, Che XY, Shen F, et al: Effective tumor vaccines generated by in vitro modification of tumor cells with cytokines and bispecific monoclonal antibodies. Nat Med 3: 451-455, 1997.